Should anti-EGFR mAbs be discontinued for conversion surgery in untreated right-sided metastatic colorectal cancer? A systematic review and meta-analysis

Datian Chen¹, Xiang Zhang², Guangyi Gao³, Lili Shen¹, Jiaqi Xie⁴, Xiaoping Qian⁴ and Huiyu Wang⁵*

Abstract

Background: Previous studies have demonstrated that left-sided tumors have better prognoses than right-sided tumors in RAS wild-type mCRC (metastatic colorectal cancer) patients, while anti-EGFR mAbs appear to have no advantage compared with bevacizumab for right-sided tumors in these patients. Nevertheless, it remains unclear whether primary tumor location affects patients’ options for potentially curative resection.

Methods: PubMed, the Cochrane Library, Embase, ASCO, and ESMO conference abstracts were searched. The inclusion criteria were RCT (randomized controlled trials) studies that evaluated the efficacy of anti-EGFR mAbs based on primary tumor location. The outcomes included ORR, ETS, and DpR. ORs for ORR were calculated with 95% confidence intervals by Comprehensive Meta-Analysis, version 2.0.

Result: Nine studies including nine RCTs were analyzed. Regardless of left- or right-sided tumors, the ORRs for anti-EGFR mAb (left-sided: 80.2%, 95% CI, 47–95%; I² = 76.9%; right-sided: 46.1%, 95% CI, 39.4–53.0%; I² = 18.9%) were both higher than the control arm including chemotherapy with or without bevacizumab. The ORs for anti-EGFR mAbs have a significant benefit compared with chemotherapy with or without bevacizumab in left-sided tumors (OR = 2.19, 95% CI, 1.41–3.38; P < 0.001). For right-sided tumors, anti-EGFR mAbs still significantly improved the ORR compared with chemotherapy alone (OR = 1.75, 95% CI, 1.05–2.90; P = 0.03), and the OR numerically favored the anti-EGFR mAbs compared with bevacizumab (OR = 1.281, 95% CI, 0.77–2.12; P = 0.335). The data of ETS and DpR from three RCTs also favored the EGFR antibody irrespective of tumor location. Resection data on differentiating tumor locations is inconclusive. For right-sided tumors, it should be noted that median PFS and OS were comparable for patients who achieved ETS in both treatment arms.

Conclusions: Anti-EGFR mAbs have advantages in the tumor shrinkage regardless of left- or right-sided tumors, which is important for conversion therapy. For right-sided tumors, anti-EGFR mAbs should remain the first choice for potentially curative resection in RAS wild-type mCRC patients. ETS may represent a subgroup of patients with right-sided tumors who might benefit from the anti-EGFR mAb.

Keywords: Metastatic colorectal cancer, Primary tumor location, Anti-EGFR mAb, Resection, Conversion therapy
Background

Colorectal cancer remains one of the most frequently diagnosed malignant neoplasms worldwide and a leading cause of cancer death [1]. Approximately 25% of patients have liver metastases at their first diagnosis, and nearly 50% of these will develop recurrent hepatic metastases during their disease [2]. Surgically resecting the metastases remains the only potentially curative strategy; however, 80–90% of patients with hepatic metastases are initially considered unresectable at diagnosis [3]. Nevertheless, due to the availability of neoadjuvant systemic chemotherapy and advanced revolutionary surgical techniques, more patients initially considered unresectable become eligible for conversion surgery following treatment. The comparable outcomes of secondary resection to those of primary resection make resectability a preferential therapeutic goal. Adam demonstrated that neoadjuvant chemotherapy allowed 12.5% of patients with previously unresectable colorectal liver metastases be rescued by surgical resections, 38% of whom had extrahepatic metastases. In certain conditions, even patients with extrahepatic metastases can be potential candidates for secondary resection [4].

Adding biologic agents to chemotherapy may further improve conversion therapy rates in patients with RAS wild-type mCRC. At present, the data seems to support a high-priority use of anti-EGFR mAb when combined with standard doublet chemotherapy regimens (FOLFIRI or FOLFOX) for converting previously unresectable metastases to potentially curative resection [5].

Recently, increasing evidence has shown that tumors arising from different sides of the colon have diverse molecular and clinical characteristics [6, 7]. Right-sided tumors are more commonly related to RAS and BRAF mutations and are CIMP-high with microsatellite instability [8–10]. Conversely, left-sided tumors are more often associated with HER2 amplification, chromosomal instability, and gene expression profiles that improve anti-EGFR mAb outcomes in patients with RAS wild-type mCRC [6, 8, 10, 11]. Two meta-analyses have shown that chemotherapy plus EGFR antibody have superior treatment outcomes compared with chemotherapy with or without bevacizumab in RAS wild-type left-sided tumors, while adding bevacizumab was numerically associated with better survival in right-sided tumors [12, 13]. Primary tumor location may help decide the treatment since it is prognostic and predicts therapeutic response. However, whether the tumor location affects the choice of targeted drugs for conversion therapy remains unclear. Because the results from 2 phase II trials showed no significant differences were observed in early tumor shrinkage and objective response rate between the tumor sidedness when cetuximab was combined with chemotherapy [14, 15]. The addition of cetuximab significantly increased the secondary resectable rate compared with chemotherapy alone [16, 17]. Thus, the impact of primary tumor sidedness on resection rates for previously unresectable metastatic CRC must be determined as well as how this connects to using targeted agents. However, resectability data are limited.

Notably, tumor response rate and resection rate have been directly correlated in studies investigating patients with unresectable colorectal liver metastases, mainly by the superior tumor lesion shrinkage [18, 19]. Tumor assessments beyond RECIST, including ETS (early tumor shrinkage) and DpR (depth of response), also suggest improved resectability. We therefore performed a systematic review and meta-analysis of randomized trials to calculate whether primary tumor location affects the choice of biologic agents for RAS wild-type mCRC patients with the opportunity for potentially curative resection.

Methods

Search strategy and selection criteria

We systematically reviewed the available data from randomized controlled trials that compared the anti-EGFR mAb with bevacizumab or chemotherapy alone based on tumor shrinkage. PubMed, Embase, and the Cochrane Library databases were searched using the following terms: colorectal, ETS, ORR, DpR, cetuximab, panitumumab, tumor sidedness, tumor location, and right-sided, left-sided, and resection. Furthermore, meeting abstracts including ASCO and ESMO were searched manually. The latest search was conducted in August 2018. To recognize additional relevant studies, all references were checked within original reports and review papers during the systematic review. Only RCT trials that reported the results evaluating EGFR antibody efficacy by tumor location in patients with RAS wild-type unresectable mCRC were retrieved. Non-English language articles were excluded. After the initial selection process, two reviewers independently screened the remaining abstracts and titles. Finally, full-text reviews were performed on studies that appeared to meet the inclusion criteria. This study followed the guidelines set by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.

Data extraction

Data were extracted from patients with RAS wild-type mCRC. Two reviewers reviewed all eligible publications and extracted the available data. For each study, data were obtained on the number of patients based on tumor location and study treatment per arm, ORR, ETS, DpR, and resection rate for patients with left-sided or right-sided tumors. Both assessments were performed in duplicate and a consensus was reached on all items. Data duplication was avoided by referencing the research center name and the author’s name. Investigators validated these data before the analyses.
### Statistical analysis

The primary endpoint of interest was ORR in RAS wild-type patients by treatment based on whether the primary tumor was left or right-sided. ETS and DpR were considered secondary endpoints. DpR data were unsuitable for meta-analysis due to their nature; therefore, DpR results are presented by the study. We calculated the weighted pooled ORR rates based on the clinically evaluable patients, using a random effects model to account for heterogeneity. The predictive value based on tumor location was investigated by comparing the ORs (chemotherapy plus anti-EGFR mAb) versus the control arms that were either chemotherapy plus bevacizumab or chemotherapy alone. An OR of > 1 indicated a favorable experimental arm containing the EGFR antibody. Subgroup analyses were performed based on the control arm. Statistical significance was considered when the \( P \) value was < 0.05. All considered tests were two-sided. Heterogeneity was evaluated by the Cochran’s \( Q \) test and the \( I^2 \) statistic. A \( P \) value < 0.10 or as an \( I^2 > 50\% \) was defined as significant heterogeneity. We evaluated publication bias using a funnel plot analysis with Begg’s and Egger’s tests. Analyses were performed using Comprehensive Meta-Analysis, version 2.exe software (BioStat, Inc.).

### Results

The initial search included 822 articles (Additional file 1: Figure S1). By excluding duplicates and screening titles/abstracts, 9 articles, including 9 first-line RCTs, were investigated in the overall analysis. Table 1 summarizes the characteristics of the 8 studies, including 555 left-sided and 1827 right-sided RAS wild-type patients. Primary tumors originating from the rectum to splenic flexure were classified as left-sided, while tumors originating from the transverse colon to caecum were considered right-sided. It is worth noting that the CALGB 80405 omitted the

### Table 1

| Study | Intervention | Number of response | Number of patients | ORR (%) | OR 95% CI | \( P \) value |
|---|---|---|---|---|---|---|
| **Right-sided colorectal cancer** | | | | | | |
| PRIME [20] | FOLFOX + panitumumab | 16 | 38 | 42.1 | 1.364 | 0.56–3.30 | 0.492 |
| | FOLFOX | 16 | 46 | 34.8 | | | |
| TAILOR [21] | FOLFOX + cetuximab | 20 | 45 | 44.4 | 2.578 | 0.99–6.67 | 0.051 |
| | FOLFOX | 9 | 38 | 23.7 | | | |
| CRYSTAL [22] | FOLFIRI + cetuximab | 1417 | 3351 | 42.4 | 1.474 | 0.60–3.64 | 0.4 |
| | FOLFIRI | | | 33.3 | | | |
| MACRO-2/PLANET [25] | FOLFIRI/FOLFOX + panitumumab | 11 | 33 | 33.3 | – | – | – |
| VOLFIL [23] | FOLFOXIRI + panitumumab | 6 | 10 | 60 | 2.500 | 0.37–16.88 | 0.347 |
| | FOLFOXIRI | 3 | 8 | 37.5 | | | |
| PEAK [20] | FOLFOX + panitumumab | 14 | 22 | 63.6 | 1.75 | 0.45–6.83 | 0.42 |
| | FOLFOX + bevacizumab | 7 | 14 | 50.0 | | | |
| FIRE-3 [24] | FOLFIRI + cetuximab | 18 | 30 | 60.0 | 1.500 | 0.57–3.95 | 0.412 |
| | FOLFIRI + bevacizumab | 19 | 38 | 50.0 | | | |
| CALGB80405 [13] | FOLFIRI/FOLFOX + cetuximab | 30 | 71 | 42.3 | 1.109 | 0.58–2.13 | 0.756 |
| | FOLFIRI/FOLFOX + bevacizumab | 31 | 78 | 39.7 | | | |
| **Left-sided colorectal cancer** | | | | | | |
| PRIME [20] | FOLFOX + panitumumab | 114 | 168 | 67.9 | 1.905 | 1.21–2.99 | 0.005 |
| | FOLFOX | 82 | 156 | 52.6 | | | |
| TAILOR [21] | FOLFOX + cetuximab | 97 | 146 | 66.4 | 2.602 | 1.63–4.13 | < 0.001 |
| | FOLFOX | 70 | 162 | 43.2 | | | |
| CRYSTAL [22] | FOLFIRI + cetuximab | 103 | 142 | 72.5 | 3.867 | 2.34–6.38 | < 0.001 |
| | FOLFIRI | 56 | 138 | 40.6 | | | |
| MACRO-2/PLANET [25] | FOLFIRI/FOLFOX + panitumumab | 78 | 148 | 52.7 | – | – | – |
| VOLFIL [23] | FOLFOXIRI + panitumumab | 48 | 53 | 90.6 | 4.518 | 1.30–15.72 | 0.018 |
| | FOLFOXIRI | 17 | 25 | 68 | | | |
| PEAK [20] | FOLFOX + panitumumab | 34 | 53 | 64.1 | 1.328 | 0.61–2.89 | 0.476 |
| | FOLFOX + bevacizumab | 31 | 54 | 57.4 | | | |
| FIRE-3 [24] | FOLFIRI + cetuximab | 93 | 124 | 75.0 | 2.115 | 1.24–3.60 | 0.006 |
| | FOLFIRI + bevacizumab | 78 | 133 | 58.6 | | | |
| CALGB80405 [13] | FOLFIRI/FOLFOX + cetuximab | 120 | 173 | 69.4 | 1.647 | 1.04–2.60 | 0.032 |
| | FOLFIRI/FOLFOX + bevacizumab | 88 | 152 | 57.9 | | | |
transverse colon from the analysis. Four RCTs [20–23] evaluated the efficacy of anti-EGFR mAb plus chemotherapy versus chemotherapy alone by tumor location, including a study in the context of a chemotherapy triplet of FOLFOXIRI. Three RCTs [13, 20, 24] evaluated the anti-EGFR mAb plus chemotherapy versus chemotherapy alone by tumor location, including a study in the context of a chemotherapy triplet of FOLFOXIRI. All patients with CRC metastases were considered unresectable at the time of the study entry. Three studies [24, 26] reported the ETS and DpR by treatment based on the tumors arising from different sides. We present the clinical outcome data efficacy below with pooled analysis results.

Overall response rate and odds ratio for ORR
Eight articles presented ORR data (complete and partial responses) for the experimental arm (anti-EGFR mAb plus chemotherapy), with a pooled ORR of 80.2% for left-sided tumors and 46.1% for right-sided tumors (left-sided: 95% CI, 47–95%; \( I^2 = 76.9\% \), Fig. 1; right-sided: 95% CI, 39.4–53.0%; \( I^2 = 18.9\% \), Fig. 2, based on the random effects model). After excluding the study containing the FOLFOXIRI regimen, the pooled ORR was 67.1% (95% CI, 61.3–72.3%; \( I^2 = 69.1\% \), Fig. 1) for left-sided and 45.5% (95% CI, 38.7–52.5%; \( I^2 = 23.0\% \), Fig. 2) for right-sided mCRC. For the control arm, the pooled ORR was 54.9% (95% CI, 43.0–66.3%; \( I^2 = 69.2\% \), Fig. 3) for left-sided tumors and 37.5% (95% CI, 27.0–49.3%; \( I^2 = 14.9\% \), Fig. 4) for right-sided tumors. Subgroups were analyzed based on doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy plus anti-VEGF antibody. Regardless of the side, the doublet regimen alone appeared to have the lowest ORR in the control arm. Anti-EGFR mAb plus chemotherapy greatly benefitted patients with left-sided tumors regardless of the control arm (OR = 2.19, 95% CI, 1.41–3.38; \( P < 0.001, I^2 = 41.2\% \), Fig. 5). The overall odds ratio for ORR numerically favored EGFR antibody in patients with right-sided tumors in first-line treatment of anti-EGFR versus anti-VEGF antibody combined with chemotherapy (OR = 1.281, 95% CI, 0.77–2.12; \( P = 0.335, I^2 = 0\% \), Fig. 6). However, the benefit remained significant for right-sided tumors in anti-EGFR therapy plus chemotherapy compared with chemotherapy alone (OR = 1.75, 95% CI, 1.05–2.90; \( P = 0.03, I^2 = 0\% \), Fig. 6).

No publication bias was seen for left-sided tumors assessed by funnel plots, as per Begg's test \( (P = 0.548) \) and Egger's test \( (P = 0.753) \). For the right-sided tumors, no obvious publication bias was observed per Egger's test \( (P = 0.108) \), but Begg's test \( (P = 0.035) \) was significant (Figs. 7 and 8).

Outcomes according to the ETS and DpR
Three RCTs [24, 26] evaluated the ETS and DpR of the anti-EGFR mAb in the first-line treatment of RAS wild-type mCRC compared with comparator treatment by tumor locations. (Table 2) In FIRE-3 and PEAK, chemotherapy plus anti EGFR mAb had higher ETS rates regardless of mCRC side (FIRE-3 71.0% vs 50.4% for left-sided, 56.7% vs 42.1% for right-sided; PEAK 58.0% vs 41% for left-sided, 55% vs 21% for right-sided). Median DpR was also better in the chemotherapy plus anti EGFR mAb versus the chemotherapy plus bevacizumab irrespective of tumor locations (FIRE-3 42.0% vs 30.8% for left-sided; 25.8% vs 17.7% for right-sided; PEAK 70% vs 48% for left-sided, 50% vs 45% for right-sided). In PRIME, chemotherapy plus anti-EGFR mAb patients achieved higher ETS rates and median DpR in patients with left-sided tumors, while ETS and median DpR were less clear in both treatment arms in patients with right-sided tumors. Due to the limited patient numbers, resectability data are not available to...
evaluate the predictive role of the anti-EGFR mAb based on tumor location. However, patients with left-sided tumors experienced more resections than patients with right-sided tumors. We also notice no obvious difference was observed between treatment arms regarding median PFS and OS in patients with right-sided tumors who achieved ETS. This means not all patients with right-sided tumors are non-responders to anti-EGFR mAb. Only one study supplied the hazard ratio, Thus, a meta-analysis is unavailable.

Discussion

Distinct differences between left- and right-sided colorectal cancer led to different prognoses. However, for patients intending to undergo radical resection, surgical resection of the left and right-sided mCRC (including mCRC with liver metastases) is the only option for a potential cure and the most important factor that affects prognosis. In this systematic review and meta-analysis, we saw no difference in EGFR antibody levels between the right- or left-sided tumors, and both had higher ORRs than chemotherapy alone. Compared with bevacizumab, anti-EGFR mAbs significantly benefit the left-sided tumors, and the OR for overall response rates in right-sided tumors also show a numerical advantage from chemotherapy plus EGFR antibody compared with chemotherapy plus bevacizumab. Unfortunately, data are limited that specifically address the tumor location’s impact on conversion therapy relative to the resection rates. Thus, a definite conclusion cannot be determined. Yet, it should be noted that median PFS and OS were comparable for patients who achieved ETS in both treatment arms, which means ETS may screen a group of patients with right-sided tumors who might respond to the anti-EGFR mAb.

Although an optimal regimen for right-sided mCRC in a neoadjuvant setting is unestablished, a regimen with a high ORR should be chosen. Among these clinical trials,
the Chinese BELIEF study, which evaluated the efficacy of adding cetuximab to chemotherapy (FOLFOX or FOLFIRI) as first-line treatment in patients with colorectal liver metastases compared to chemotherapy alone, may be of paramount importance. The cetuximab combination significantly increased the secondary resectable rate compared with chemotherapy alone (25.7% vs 7.4%). Patients in the cetuximab plus chemotherapy arm experienced greater objective response rates (57.1% vs 29.4%; \( P < .01 \)) and longer survival (median 30.9 vs 21.0 months). Upon assessing the extended RAS mutation status, the cetuximab-induced therapeutic effects were numerically more pronounced [16, 17]. Another clinical trial, CELIM, confirmed the value of conversion chemotherapy managed within a multidisciplinary team and demonstrated a superior outcome in patients with unresectable liver-limited metastases involving a neoadjuvant treatment followed by liver metastasis resection. Both regimens (cetuximab plus FOLFOX or FOLFIRI) yielded high responses and increased resection rates [27, 28]. The PLANET study, which evaluated panitumumab plus FOLFOX or FOLFIRI, had the similar results [29]. There are also studies exploring the bevacizumab in unresectable lesions that are potentially convertible to resectability. The addition of bevacizumab to irinotecan-based regimens improved the response rate, while bevacizumab showed no benefit to the oxaliplatin-based regimens with regard to the response rate [30–32]. Despite the lack of direct data comparing first-line anti-EGFR mAb with bevacizumab in the conversion setting for potentially curative resection in RAS wild-type mCRC, higher ORRs were observed in right-sided patients treated with anti-EGFR mAb. This promotes the

---

**Table 1**

| Model | Group by category | Study name | Subgroup within study | Statistics for each study | Odds ratio and 95% CI |
|-------|-------------------|------------|-----------------------|--------------------------|----------------------|
|       |                   |            |                       |                           |                      |
|       |                   |            |                       | Event rate               | Lower limit          | Upper limit          | Z-Value | p-Value |
| Doublet | PRIME             | left       |                       | 1.903                    | 2.091                | 2.800                | 0.005   |
| Doublet | TAILOR            | left       |                       | 2.002                    | 1.837                | 4.235                | 0.000   |
| Doublet | CRYSTAL           | left       |                       | 3.847                    | 2.143                | 6.884                | 0.000   |
| Doublet | VOLFJ             | left       |                       | 4.518                    | 3.288                | 6.638                | 0.000   |
| Fixed  | CT                |             |                       | 2.556                    | 2.503                | 7.278                | 0.000   |
| Random  | CT                |             |                       | 2.704                    | 2.605                | 4.511                | 0.000   |
| Random  | CT+BV             | PEAK       | left                  | 1.328                    | 0.310                | 5.902                | 0.476   |
| Random  | CT+BV             | FIRE3      | left                  | 2.115                    | 1.241                | 3.565                | 0.006   |
| Random  | CT+BV             | CALGB80405 | left                  | 1.647                    | 1.043                | 2.596                | 0.032   |
| Fixed  | CT+BV             | 1.735       | 1.285                 | 3.883                    | 2.383                | 3.413                | 0.001   |
| Random  | CT+BV             | 1.735       | 1.218                 | 3.459                    | 3.060                | 3.002                | 0.002   |
| Fixed  | Overall           |            |                       | 2.239                    | 1.827                | 2.746                | 0.000   |
| Random  | Overall           |            |                       | 2.185                    | 1.811                | 3.585                | 0.000   |

**Fig. 4** Forest plots for pooled ORR of right-sided tumors in control arm. Doublet, doublet chemotherapy; triplet, triplet chemotherapy; BV, bevacizumab

**Fig. 5** Forest plots showing odds ratio (OR) for overall response rate (ORR) comparing anti-EGFR antibody plus chemotherapy with control arm for the left-sided mCRC. CT, chemotherapy; BV, bevacizumab
idea that in RAS wild-type patients with right-sided tumors, EGFR antibody should remain the first choice for conversion therapy.

Superior novel response-related endpoints are being investigated in mCRC trials to measure temporal and quantitative tumor burden alterations beyond those provided by RECIST. Early tumor shrinkage (ETS), which is defined as an approximately 20% reduction in the sum of the largest tumor lesion diameters evaluated during early radiological assessment after 6–8 weeks from baseline, represent a good prognostic factor in colorectal cancer [33], while DpR assesses the maximum change in tumor size achieved during treatment [34]. In the FIRE-3 study, ETS and DpR, acquired by centralized...
radiological review, were both associated with improved overall survival irrespective of treatment (FOLFIRI plus cetuximab vs with FOLFIRI plus bevacizumab) in the RAS wild-type population [35]. Furthermore, FOLFIRI plus cetuximab enhanced ETS and DpR compared with the FOLFIRI plus bevacizumab group. Retrospective analyses from the CRYSTAL and OPUS clinical trials also revealed that the cetuximab combinations to first-line chemotherapy enhanced the ETS and DpR frequencies, and these parameters were linked with long-term outcomes in mCRC patients [36, 37].

Clinically obtaining the ETS and maximal DpR will likely exclusively benefit patients who are potential candidates for conversion resection. In the PRIME and PEAK studies, patients receiving panitumumab had higher ETS rates and greater DpR than those without panitumumab [38]. ETS and DpR improved PFS, OS and resection rates. Most resections occurred in patients from the highest DpR categories. The randomized phase 2 trial, PLANET, reported a head-to-head trial of panitumumab plus FOLFOX4 versus panitumumab plus FOLFIRI in the first-line treatment of mCRC and showed both regimens have a high ETS and ORR, allowing potentially curative resection [38]. Shrinkage should be achieved early to allow resection in potentially resectable patients as soon as possible to avoid surgical complications from prolonged treatment or potential liver toxicities.

Although the ORR, ETS and DpR favored the EGFR antibody in right-sided tumors for RAS wild-type mCRC patients, left-sided tumors had better prognoses regardless of treatment. The molecular differences in BRAF and NRAS mutations and CIMP-high and gene expression in tumor sidedness may account for this since the effect of primary tumor location was not significant on multivariate analysis [39]. Recently, the four consensus molecular subtypes (CMSs) emerged with marked differences: CMS1 (MSI immune), CMS2 (canonical), CMS3 (metabolic) and CMS4 (mesenchymal). The important biologic distinctions may explain the differential responses to targeted therapy between primary tumor locations [40, 41].

Luckily, triplet chemotherapy can overcome this obstacle. In the TRIBE study, FOLFOXIRI plus bevacizumab improved mCRC patient outcomes compared with the FOLFIRI plus bevacizumab, and the treatment effect was unaffected by BRAF and RAS status [42]. Interestingly, a pooled analysis assessing the efficacy of FOLFOXIRI plus bevacizumab demonstrated a 69% ORR and 39.1% surgical conversion [43]. In our study, adding panitumumab to FOLFOXIRI increased the overall response rate from 60.0 to 90.6% in left-sided tumors and 37.5 to 60% for right-sided tumors in patients with RAS wild-type unresectable mCRC. The overall resections were 60%
versus 36.4% (FOLFOXIRI plus panitumumab vs FOLFIRI). Thus, triplet chemotherapy may be the preferred therapy option for right-sided tumors, but considering the toxicity, the standard doublet chemotherapy is more rational.

We acknowledge several limitations to these analyses. First, most data were derived from retrospectively analyzing radiologic imaging rather than a formal, prospective, analysis at fixed, pre-defined time points. Many of the presented data were derived from abstract-only presentations, even if they referred to large, historical, randomized trials with long follow-ups. Second, the patients analyzed are only an unselected metastatic population; thus, the ORR may have differed in metastasis. Furthermore, as we could not access patient-level data from all studies, only a study-level meta-analysis of ORR could be performed, and only three studies evaluated the ETS and DpR. Most importantly, resection data were limited for the tumor location; however, the change in tumor size related to the conversion surgery directly. Thus, we believe that good tumor response increases the resectability rate.

**Conclusion**

In conclusion, our findings suggest that anti-EGFR mAb plus chemotherapy may offer better tumor shrinkage than chemotherapy alone or combined with bevacizumab in patients with RAS wild-type mCRC regardless of tumor location, which may translate into consistent probabilities for undergoing secondary resection. ETS may screen a group of patients with right-sided tumors who might respond to the anti-EGFR mAb. Therefore, more prospective RCTs are urgently needed to confirm the optimized conversion strategy for right-sided mCRC.

### Additional file

**Additional file 1: Figure S1.** Flow chart showing literature search and study. (PDF 87 kb)

**Abbreviations**

DpR: Depth of response; ETS: Early tumor shrinkage; ORR: Objective response rate

**Acknowledgements**

All authors declare that this paper has no sources of funding.

**Availability of data and materials**

All data analyzed during this study are included in this published article.

**Authors’ contributions**

DTC and HYW conceived the study. DTC collected the data and drafted the manuscript. XZ, GYG, LLS, JQX, and XP revised the manuscript. HYW contacted the authors. All authors read and approved the final manuscript.

---

**Table 2** ETS, DpR and outcomes according to the primary tumor location in three RCTs

| Characteristic | PRIME | FIRE-3 | PEAK |
|---------------|-------|--------|------|
|                | Left-sided | Right-sided | Left-sided | Right-sided | Left-sided | Right-sided |
|                | Pani+FOFOX (n=169) | FOFOX (n=152) | Pani+FOFOX (n=39) | FOFOX (n=49) | Cet+FOFLIRI (n=124) | Bev+FOFLIRI (n=133) | Cet+FOFLIRI (n=30) | Bev+FOFLIRI (n=38) | Pani+mfOLF6OX (n=53) | Bev+mfOLF6OX (n=54) | Pani+mfOLF6OX (n=22) | Bev+mfOLF6OX (n=14) |
| ETS n (%)      | 104 (62) | 57 (36) | 12 (31) | 15 (31) | 104 (62) | 57 (36) | 12 (31) | 15 (31) | 104 (62) | 57 (36) | 12 (31) | 15 (31) |
| Median OS (95% CI), months | 14.8 (12.5–18.5) | 11.1 (9.3–13.9) | 14.9 (7.4–27.2) | 7.3 (5.6–11.1) | 17.8 (2.1–20.5) | 13.4 (3.8–21.2) | 7.8 (2.1–20.5) | 13.4 (3.8–21.2) | 88 (71) | 67 (50.4) | 17 (56.7) | 16 (42.1) |
| Median DpR % | 59 49 37 50 42 30.8 25.8 17.7 70 48 50 45 | 19 (11) | 16 (10) | 2 (5) | 1 (2) | 9 (17) | 10 (19) | 2 (9) | 1 (7) | 7 (13) | 6 (11) | 1 (5) | 1 (7) |

ETS status was unknown for some patients only. FIRE-3 reported the HR for PFS and OS. NR not reported, NE not evaluable, cet cetuximab, Pani+ panitumumab, Bev+ bevacizumab.
Ethics approval and consent to participate
This article does not contain any studies with human participants or animals performed by any of the authors.

Consent for publication
Not applicable

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Department of Oncology, Haimen People’s Hospital, Haimen, China. 2 Nanjing Drum Tower Hospital, Clinical College of Nanjing Medical University, Nanjing, China. 3 The Comprehensive Cancer Center, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China. 4 The Comprehensive Cancer Center of Drum Tower Hospital, Medical School of Nanjing University and Clinical Cancer Institute of Nanjing University, Nanjing, China. 5 Wuxi People’s Hospital affiliated to Nanjing Medical University, Wuxi, China.

Revised: 21 May 2018 Accepted: 28 September 2018
Published online: 08 October 2018

References
1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30.
2. Garden OJ, Rees M, Poston GJ, et al. Guidelines for resection of colorectal cancer liver metastases. Gut. 2006;55(suppl 3):i1–i8.
3. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases staged down by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):564–57.
4. Johnston KM, Kneuerz PJ, Pavlik TM. Resection of non-hepatic colorectal cancer metastasis. J Gastrointest Oncol. 2012;3(1):59–68.
5. Poston G, Adam R, Xu J, Byrne B, Esser R, et al. The role of cetuximab in converting initially unresectable colorectal cancer liver metastases for resection. Eur J Surg Oncol. 2017;43(1):2001–11.
6. Missiaglia E, Jacobs B, D’Ario G, Di Nardo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995e2001.
7. Aarts F, de Hingh I, de Wilt JHW, et al. Differences in outcome between right- and left-sided colon cancer: a population based study. J Clin Oncol. 2013;31(suppl 4):Abstract 493.
8. Gunney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015;21:1350–6.
9. Lee MS, McCueffey EJ, Morris JS, et al. Association of CpG island methylator phenotype and EREG/AREG methylation and expression in colorectal cancer. Br J Cancer. 2016;114:1352–61.
10. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.
11. Jacobs B, De Roock W, Piessevaux H, et al. Amphiregulin and epiregulin mRNA expression in primary tumors predicts outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2009;27:5068–74.
12. Holch JW, Ricard I, Stintzing S, et al. The relevance of primary tumor location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer. 2017;70:77–87.
13. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with KRAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017;28(8):1713–29.
14. Sunakawa Y, Ichikawa W, Tsuji A, et al. Prognostic impact of primary tumor location on clinical outcomes of metastatic colorectal cancer treated with cetuximab plus oxaliplatin-based chemotherapy: a subgroup analysis of the JACCRO CC-05/06 trials. Clin Colorectal Cancer. 2016; [Epub ahead of print].
15. Sunakawa Y, Tsuji A, Fuji M, Ichikawa W. No benefit from the addition of anti-EGFR antibody in all right-sided metastatic colorectal cancer? Ann Oncol. 2017;28(8):2030–1.
16. Ye LC, Liu TS, Ren L, Wei Y, Zhu DX, Zai SY, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;31(16):1931e8.
17. Xu J, Ren L, Wei Y, Zheng P, Ye L, Feng Q, et al. Effects of beyond KRAS mutations on the efficacy of cetuximab plus chemotherapy for patients with unresectable colorectal liver-limited metastases (BELIEF): a retrospective biomarker analysis from a Chinese population. Ann Oncol. 2016;27(suppl 10):abstract S41P.
18. Jones RP, Hamann S, Malik HZ, Fenwick SW, Poston GJ, Folprecht G. Defined criteria for resectability improves rates of secondary resection after systemic therapy for liver limited metastatic colorectal cancer. Eur J Cancer. 2014; 50(9):1590–601.
19. Folprecht G, Groothey A, Alberts S, Raab HR, Kohn CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16(8):1311–9.
20. Boeckx N, Koukakis R, Op de Breeek K, et al. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. Ann Oncol. 2017;28(8):1862–8.
21. Qin S, Xu J, Wang L. The impact of primary tumor location (TL) on outcomes of first-line (1L) FOLFOX-4 (F) vs cetuximab (cet) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 3 TAILOR trial. ASCO-GI 2017 abstr 683. 2017.
22. Teijar S, Stintzing S, Giardelio F, Tabernero J, Van Cutsem E, Beier F, et al. Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the KRK-0306 trial. JAMA Oncol. 2016; https://doi.org/10.1001/jamaoncol.2016.3797.
23. Geissler M, Martens UM, Knoorenriedli R, et al. mFOLFOXIRI 1 panitumumab versus FOLFOXIRI as first-line treatment in patients with RAS wild-type metastatic colorectal cancer (mCRC): A randomized phase II VolFI trial of the AIO (AIO-KRK0109). Ann Oncol. 2017;28(suppl 5):Abstr 583P.
24. Holch JW, Stintzing S, Held S, Fischer von Weikertsh L, Becker T, Kani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Kahl C, Kullmann F, Scheithauer W, Kirchner T, von Einem JC, Modest DP, Heinemann V. Right-sided colorectal cancer (RC): response to first-line chemotherapy in FIRE3 (AIO-KRK-0306) with focus on early tumor shrinkage (ETS) and depth of response (DPR). J Clin Oncol. 2017;35(suppl):3586.
25. Benavides M, Canato A, Abad A, et al. Impact of tumor location on the efficacy of first-line anti-EGFR monoclonal antibody plus chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC). Retrospective analyses of the randomized MACRO-2 and PLANET trials from TSGT Group. Ann Oncol. 2017;28(suppl 5):Abstr 475P.
26. Peeters M, Price T, Taebj J, Geissler M, et al. Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018;119(9):303–12.
27. Folprecht G, Gruenberg J, Bechstein WD, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11(1):684e7.
28. Folprecht G, Gruenberg J, Bechstein WD, Raab HR, Weitz J, Lordick F, et al. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFOXIRI/cetuximab in a multidisciplinary setting: first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. Br J Cancer. 2018;119(9):303–12.
29. Carrato A, Abad A, Masotti B, et al. First-line panitumumab plus FOLFIRI4 or FOLFOX4 in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017;81:191–202.
30. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluorouracil/5-fluorouracil in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779–86.
31. Huwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–42.
32. Saltz LB, Clarke S, Diaz-Rubio E, et al. Randomized controlled trial with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–9.
33. Petrelli F, Pietrantonio F, Cerolimni C, et al. Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis. Eur J Cancer. 2015;51(7):800–7.
34. Heinemann V, Stintzing S, Modest DP, Giessen-Jung C, Michl M, Mansmann UR. Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC). Eur J Cancer. 2015;51:1927–36.

35. Stintzing S, Modest DP, Rossius L, Lech MA, von Wekerthol LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol. 2016;17:1426e34 https://doi.org/10.1016/S1470-2045(16)30269-8.

36. Piessevaux H, Buyse M, Schlichting M, et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol. 2013;31:3764–75.

37. Mansmann UR, Sartorius U, Laubender RP, Giessen CA, Esser R, Heinemann V. Depth of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. Proc Am Soc Clin Oncol. 2013;31(suppl 4):abstr 427.

38. Taieb J, Rivera F, Siena S, et al. Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials. J Cancer Res Clin Oncol. 2018;144(2):321–35.

39. Lee MS, Advani SM, Morris J et al. Association of primary site and molecular features with progression-free survival and overall survival of metastatic colorectal cancer after anti-epidermal growth factor receptor therapy. J Clin Oncol 2016; 34(suppl); abstr 3506 http://meetinglibrary.asco.org/content/171167-176/ (Accessed 30 Mar).

40. Dunne PD, et al. Challenging the cancer molecular stratification dogma: intratumoral heterogeneity undermines consensus molecular subtypes and potential diagnostic value in colorectal cancer. Clin Cancer Res. 2016;22(16):4095–104.

41. Lee MS, Menter DG, Kopetz S. Right versus left colon cancer biology: integrating the consensus molecular subtypes. J Natl Compr Cancer Netw. 2017;15(3):411–9.

42. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306–15.

43. Tomaseo G, Petrelli F, Ghidini M, Russo A, Passalacqua R, Banni S. FOLFIRI plus bevacizumab as conversion therapy for patients with initially unresectable metastatic colorectal cancer: a systematic review and pooled analysis. JAMA Oncol. 2017;3(7):e170278.